Compounds > 2-methyl-1H-pyrimido[1,2-a]benzimidazol-4-one
Page last updated: 2024-12-08

2-methyl-1H-pyrimido[1,2-a]benzimidazol-4-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID486631
CHEMBL ID1606695
CHEBI ID123191
SCHEMBL ID12395170
SCHEMBL ID19411063

Synonyms (46)

Synonym
EU-0063313
MLS000123309
smr000123999
2-methyl-4-oxo-1,4a,9-triazafluorene
2-methyl-benzo[4,5]imidazo[1,2-a]pyrimidin-4-ol
pyrimido[1,2-a]benzimidazol-4-ol, 2-methyl-
2-methylpyrimido[1,2-a]benzimidazol-4-ol
SR-01000641272-1
2-methylpyrimido[1,2-a]benzimidazol-4(1h)-one
STK211466
CHEBI:123191
2-methylpyrimido[1,2-a]benzimidazol-4(10h)-one
STL044738
AKOS000676603
2-methyl-1h-pyrimido[1,2-a]benzimidazol-4-one
AKOS001261932
HMS2458A08
AKOS005698084
CCG-34160
CCG-21411
CCG-52014
50290-51-2
CHEMBL1606695
SCHEMBL12395170
2-methyl-1h-benzo[4,5]imidazo[1,2-a]pyrimidin-4-one
GGBPUPFQFFGKLR-UHFFFAOYSA-N
2-methylpyrimido[1,2-a]benzimidazole-4-ol
2-methylpyrimido[1,2-a]benzimidazol-4-ol #
GDUPORKSABXXOG-UHFFFAOYSA-N
SR-01000502148-1
sr-01000502148
Q27212862
DTXSID70333150
2-methylpyrimido[1,2-a][1,3]benzimidazol-4(1h)-one
mfcd00859063
sr-01000580269
SR-01000580269-1
11-methyl-1,8,10-triazatricyclo[7.4.0.0?,?]trideca-2,4,6,8,11-pentaen-13-one
SCHEMBL19411063
2-methylbenzo[4,5]imidazo[1,2-a]pyrimidin-4(1h)-one
pyrimido[1,2-a]benzimidazol-4(1h)-one,2-methyl-(9ci)
LS-05497
11-methyl-1,8,10-triazatricyclo[7.4.0.0(2),?]trideca-2,4,6,8,11-pentaen-13-one
2-methylbenzo[4,5]imidazo[1,2-a]pyrimidin-4(10h)-one
CS-0314759
Z57721177
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency31.62280.100020.879379.4328AID588456
ClpPBacillus subtilisPotency14.12541.995322.673039.8107AID651965
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency31.62283.548119.542744.6684AID743266
survival motor neuron protein isoform dHomo sapiens (human)Potency28.18380.125912.234435.4813AID1458
Guanine nucleotide-binding protein GHomo sapiens (human)Potency2.23871.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID103712In vitro cytotoxic activity against MCF-7 (human breast cancer) cell line.1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID201791In vitro cytotoxic activity was determined against melanoma cancer (SK-MEL-2) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID357033Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication2001Journal of natural products, Jul, Volume: 64, Issue:7
Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives.
AID213901In vitro cytotoxic activity was determined against glioblastoma (U-87-MG) cell line; Not active1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID8467In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID357032Cytotoxicity against human H9 cells2001Journal of natural products, Jul, Volume: 64, Issue:7
Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives.
AID2964In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID95653In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID42569In vitro cytotoxic activity was determined against renal cancer (CAKI-1) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID202392In vitro cytotoxic activity was determined against osteosarcoma (SaOS-2) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.86 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		210azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
norharman
norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.		210beta-carbolines;
mancude organic heterotricyclic parent		fungal metabolite;
marine metabolite
harmol
harmol: harmol is oxidized form of alkaloid harmolol; RN given refers to parent cpd; structure		2.4120harmala alkaloid
matairesinol
matairesinol: lignan that is a central precursor in plants in the biosynthesis of numerous lignans (coordinate with specific); RN refers to (3R-trans)-isomer. (-)-matairesinol : A lignan that is gamma-butyrolactone in which the 3 and 4 positions are substituted by 4-hydroxy-3-methoxybenzyl groups (the 3R,4R-diastereomer).		210gamma-lactone;
lignan;
polyphenol		angiogenesis inhibitor;
anti-asthmatic agent;
phytoestrogen;
plant metabolite
harmalol hydrochloride
[no description available]		210
harmalan
harmalan: structure given in first source		210harmala alkaloid
isolariciresinol
isolariciresinol: RN given refers to ((1-S-(1alpha,2beta,3alpha))-isomer); structure given in first source. (+)-isolariciresinol : A lignan that is 5,6,7,8-tetrahydronaphthalen-2-ol substituted by hydroxymethyl groups at positions 6 and 7, a methoxy group at position 3 and a 4-hydroxy-3-methoxyphenyl group at position 8. It has been isolated from the roots of Rubia yunnanensis.		210guaiacols;
lignan;
polyphenol;
primary alcohol		plant metabolite
N-ethylharmine
N-ethylharmine : A member of the class of beta-carbolines that is 9H-beta-carboline substituted by a ethyl group at position 9, methoxy group at position 7 and a methyl group at position 1. It is semisynthetic derivative of harmine and has been shown to exhibit significant anti-HIV activity.		2.4120aromatic ether;
beta-carbolines;
semisynthetic derivative		anti-HIV agent
harmine
Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.		2.4120harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
harman
harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.		2.4120harmala alkaloid;
indole alkaloid fundamental parent;
indole alkaloid		anti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
(-)-pinoresinol
(-)-pinoresinol : An enantiomer of pinoresinol having (-)-1R,3aS,4R,6aS-configuration.		210pinoresinolplant metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510